Literature DB >> 19670425

Experimental models for hepatitis C viral infection.

Andre Boonstra1, Luc J W van der Laan, Thomas Vanwolleghem, Harry L A Janssen.   

Abstract

Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease. The majority of infected individuals develop a persistent infection, which is associated with a high risk of liver cirrhosis and hepatocellular carcinoma. Since its discovery 20 years ago, progress in our understanding of this virus has been suboptimal due to the lack of good model systems. However, in the past decade this has greatly accelerated with the development of various in vitro cell culture systems and in vivo small-animal models. These systems have made a major impact on the field of HCV research, and have provided important breakthroughs in our understanding of HCV infection and replication. Importantly, the in vitro cell culture systems and the small-animal models have allowed preclinical testing of numerous novel antiviral compounds for the treatment of chronic HCV infection. In this article, we give an overview of current models, discuss their limitations, and provide future perspectives for research directed at the prevention and cure of hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19670425     DOI: 10.1002/hep.23138

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  30 in total

Review 1.  Embryonic and induced pluripotent stem cells as a model for liver disease.

Authors:  Hiroshi Yagi; Edgar Tafaleng; Masaki Nagaya; Marc C Hansel; Stephen C Strom; Ira J Fox; Alejandro Soto-Gutierrez
Journal:  Crit Rev Biomed Eng       Date:  2009

2.  Cytokeratin 8 is increased in hepatitis C virus cells and its ectopic expression induces apoptosis of SMMC7721 cells.

Authors:  Ming-Zhu Sun; Shuang-Suo Dang; Wen-Jun Wang; Xiao-Li Jia; Song Zhai; Xin Zhang; Mei Li; Ya-Ping Li; Meng Xun
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

3.  Comparative analysis of NK-cell receptor expression and function across primate species: Perspective on antiviral defenses.

Authors:  Roberto Biassoni; Elisabetta Ugolotti; Andrea De Maria
Journal:  Self Nonself       Date:  2010-03-06

4.  Ineffective CD8(+) T-cell immunity to adeno-associated virus can result in prolonged liver injury and fibrogenesis.

Authors:  Jessica Spahn; Robert H Pierce; Ian N Crispe
Journal:  Am J Pathol       Date:  2011-09-15       Impact factor: 4.307

5.  Ly6Chi monocytes regulate T cell responses in viral hepatitis.

Authors:  Jiangao Zhu; Huiyao Chen; Xiaopei Huang; Songfu Jiang; Yiping Yang
Journal:  JCI Insight       Date:  2016-10-20

6.  Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans.

Authors:  Mark A A Claassen; Robert J de Knegt; Harry L A Janssen; André Boonstra
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

Review 7.  Sofosbuvir and ABT-450: terminator of hepatitis C virus?

Authors:  Qing-Lei Zeng; Ji-Yuan Zhang; Zheng Zhang; Li-Feng Wang; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

8.  Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication.

Authors:  Silvia Giugliano; Michael Kriss; Lucy Golden-Mason; Evgenia Dobrinskikh; Amy E L Stone; Alejandro Soto-Gutierrez; Angela Mitchell; Salman R Khetani; Daisuke Yamane; Mark Stoddard; Hui Li; George M Shaw; Michael G Edwards; Stanley M Lemon; Michael Gale; Vijay H Shah; Hugo R Rosen
Journal:  Gastroenterology       Date:  2014-11-04       Impact factor: 22.682

Review 9.  Targeting viral infection by microRNA inhibition.

Authors:  Ashley P E Roberts; Catherine L Jopling
Journal:  Genome Biol       Date:  2010-01-26       Impact factor: 13.583

10.  Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.

Authors:  Eric Lawitz; Maribel Rodriguez-Torres; Jill M Denning; Efsevia Albanis; Melanie Cornpropst; Michelle M Berrey; William T Symonds
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.